NVAX vs. TWST, IOVA, DNLI, RLAY, ADPT, EXAS, RGEN, EXEL, HALO, and IONS
Should you be buying Novavax stock or one of its competitors? The main competitors of Novavax include Twist Bioscience (TWST), Iovance Biotherapeutics (IOVA), Denali Therapeutics (DNLI), Relay Therapeutics (RLAY), Adaptive Biotechnologies (ADPT), Exact Sciences (EXAS), Repligen (RGEN), Exelixis (EXEL), Halozyme Therapeutics (HALO), and Ionis Pharmaceuticals (IONS). These companies are all part of the "medical" sector.
Twist Bioscience (NASDAQ:TWST) and Novavax (NASDAQ:NVAX) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, community ranking, media sentiment, analyst recommendations, risk, dividends and valuation.
Novavax received 754 more outperform votes than Twist Bioscience when rated by MarketBeat users. Likewise, 74.14% of users gave Novavax an outperform vote while only 56.69% of users gave Twist Bioscience an outperform vote.
Twist Bioscience presently has a consensus target price of $42.50, suggesting a potential upside of 1.43%. Novavax has a consensus target price of $17.50, suggesting a potential upside of 16.43%. Given Twist Bioscience's higher probable upside, analysts clearly believe Novavax is more favorable than Twist Bioscience.
53.0% of Novavax shares are owned by institutional investors. 3.9% of Twist Bioscience shares are owned by insiders. Comparatively, 0.9% of Novavax shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Twist Bioscience has a beta of 1.64, indicating that its stock price is 64% more volatile than the S&P 500. Comparatively, Novavax has a beta of 1.63, indicating that its stock price is 63% more volatile than the S&P 500.
Novavax has a net margin of -40.01% compared to Novavax's net margin of -69.24%. Twist Bioscience's return on equity of 0.00% beat Novavax's return on equity.
Twist Bioscience has higher earnings, but lower revenue than Novavax. Twist Bioscience is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.
In the previous week, Novavax had 1 more articles in the media than Twist Bioscience. MarketBeat recorded 6 mentions for Novavax and 5 mentions for Twist Bioscience. Novavax's average media sentiment score of 1.14 beat Twist Bioscience's score of 0.63 indicating that Twist Bioscience is being referred to more favorably in the media.
Summary
Novavax beats Twist Bioscience on 11 of the 18 factors compared between the two stocks.
Get Novavax News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVAX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
